HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs

Multiple myeloma (MM), a malignant plasma cell infiltration of the bone marrow, is generally considered incurable: resistance to multiple therapeutic drugs inevitably arises from tumor cell-intrinsic and tumor microenvironment (TME)-mediated mechanisms. Here we report that the proteoglycan tandem re...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Mailee, Chang, Hae Yeun, Lisiero, Dominique N., Ong, Irene M., Kashyap, Trinayan, Callander, Natalie S., Miyamoto, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045543/
https://www.ncbi.nlm.nih.gov/pubmed/36480501
http://dx.doi.org/10.1371/journal.pone.0274704
_version_ 1784913629290692608
author Huynh, Mailee
Chang, Hae Yeun
Lisiero, Dominique N.
Ong, Irene M.
Kashyap, Trinayan
Callander, Natalie S.
Miyamoto, Shigeki
author_facet Huynh, Mailee
Chang, Hae Yeun
Lisiero, Dominique N.
Ong, Irene M.
Kashyap, Trinayan
Callander, Natalie S.
Miyamoto, Shigeki
author_sort Huynh, Mailee
collection PubMed
description Multiple myeloma (MM), a malignant plasma cell infiltration of the bone marrow, is generally considered incurable: resistance to multiple therapeutic drugs inevitably arises from tumor cell-intrinsic and tumor microenvironment (TME)-mediated mechanisms. Here we report that the proteoglycan tandem repeat 1 (PTR1) domain of the TME matrix protein, hyaluronan and proteoglycan link protein 1 (HAPLN1), induces a host of cell survival genes in MM cells and variable resistance to different classes of clinical drugs, including certain proteasome inhibitors, steroids, immunomodulatory drugs, and DNA damaging agents, in several MM cell lines tested. Collectively, our study identifies HAPLN1 as an extracellular matrix factor that can simultaneously confer MM cell resistance to multiple therapeutic drugs.
format Online
Article
Text
id pubmed-10045543
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-100455432023-03-29 HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs Huynh, Mailee Chang, Hae Yeun Lisiero, Dominique N. Ong, Irene M. Kashyap, Trinayan Callander, Natalie S. Miyamoto, Shigeki PLoS One Research Article Multiple myeloma (MM), a malignant plasma cell infiltration of the bone marrow, is generally considered incurable: resistance to multiple therapeutic drugs inevitably arises from tumor cell-intrinsic and tumor microenvironment (TME)-mediated mechanisms. Here we report that the proteoglycan tandem repeat 1 (PTR1) domain of the TME matrix protein, hyaluronan and proteoglycan link protein 1 (HAPLN1), induces a host of cell survival genes in MM cells and variable resistance to different classes of clinical drugs, including certain proteasome inhibitors, steroids, immunomodulatory drugs, and DNA damaging agents, in several MM cell lines tested. Collectively, our study identifies HAPLN1 as an extracellular matrix factor that can simultaneously confer MM cell resistance to multiple therapeutic drugs. Public Library of Science 2022-12-08 /pmc/articles/PMC10045543/ /pubmed/36480501 http://dx.doi.org/10.1371/journal.pone.0274704 Text en © 2022 Huynh et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Huynh, Mailee
Chang, Hae Yeun
Lisiero, Dominique N.
Ong, Irene M.
Kashyap, Trinayan
Callander, Natalie S.
Miyamoto, Shigeki
HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs
title HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs
title_full HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs
title_fullStr HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs
title_full_unstemmed HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs
title_short HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs
title_sort hapln1 confers multiple myeloma cell resistance to several classes of therapeutic drugs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045543/
https://www.ncbi.nlm.nih.gov/pubmed/36480501
http://dx.doi.org/10.1371/journal.pone.0274704
work_keys_str_mv AT huynhmailee hapln1confersmultiplemyelomacellresistancetoseveralclassesoftherapeuticdrugs
AT changhaeyeun hapln1confersmultiplemyelomacellresistancetoseveralclassesoftherapeuticdrugs
AT lisierodominiquen hapln1confersmultiplemyelomacellresistancetoseveralclassesoftherapeuticdrugs
AT ongirenem hapln1confersmultiplemyelomacellresistancetoseveralclassesoftherapeuticdrugs
AT kashyaptrinayan hapln1confersmultiplemyelomacellresistancetoseveralclassesoftherapeuticdrugs
AT callandernatalies hapln1confersmultiplemyelomacellresistancetoseveralclassesoftherapeuticdrugs
AT miyamotoshigeki hapln1confersmultiplemyelomacellresistancetoseveralclassesoftherapeuticdrugs

Ejemplares similares